

CLAIMS

1. A neutralising antibody that specifically binds to the receptor binding domain (RBD) of the SARS-CoV-2 spike protein, wherein the antibody competes for binding to the SARS-CoV-2 spike protein with the human ACE2 receptor.

2. An antibody according to claim 1, wherein the antibody comprises a variable heavy (VH) domain sequence comprising complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3, and a variable light (VL) domain sequence comprising complementarity determining regions LCDR1, LCDR2 and LCDR3, and wherein HCDR3 is the HCDR3 of antibody IMPI-037 as shown in Table 1a (SEQ ID NO: 182).

3. An antibody according to claim 2, wherein the 6 CDRs are those of antibody IMPI-037 as shown in Table 1a (SEQ ID NOS: 180 to 182, 185, 18, and 186).

4. An antibody according to claim 3, wherein the variable heavy (VH) domain and variable light (VL) domain sequences respectively comprise

i. the variable heavy (VH) domain and variable light (VL) domain sequences of antibody IMPI-037 as shown in Table 1a (SEQ ID NOS: 179 and 184), optionally with 1, 2, 3, 4 or 5 amino acid alterations outside the complementarity determining regions (CDRs) in the variable heavy (VH) domain sequence and optionally with 1, 2, 3, 4 or 5 amino acid alterations outside the complementarity determining regions (CDRs) in the variable light (VL) domain sequence; or

~~5. An antibody according to claim 3, wherein the variable heavy (VH) domain and variable light (VL) domain sequences respectively comprise~~

ii. a sequence having at least 90% identity to the variable heavy (VH) and variable light (VL) domain sequences of antibody IMPI-037 as shown in Table 1a, provided that the antibody has the 6 CDRs of antibody IMPI-037 as shown in Table 1a.

~~65.~~ An antibody according to any preceding claim, wherein the variable heavy (VH) domain and variable light (VL) domain sequences respectively comprise the variable heavy (VH) and variable light (VL) domain sequences of antibody IMPI-037 as shown in Table 1a.

~~7. An antibody according to claim 1, wherein the antibody comprises a variable heavy (VH) domain sequence comprising complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3, and a variable light (VL) domain sequence comprising complementarity~~

determining regions ~~LCDR1, LCDR2 and LCDR3~~, wherein ~~HCDR3~~ is the ~~HCDR3~~ of antibody ~~YANG-1112, YANG-2107, YANG-2108, or YANG-2111~~ as shown in Table 1b.

	~~YANG-1112~~	~~YANG-2107~~	~~YANG-2108~~	~~YANG-2111~~
~~HCDR3~~	~~SEQ ID No: 574~~	~~SEQ ID No: 901~~	~~SEQ ID No: 910~~	~~SEQ ID No: 1048~~

8. ~~An antibody according to claim 7, wherein the 6 CDRs are those of one of antibody YANG-1112, YANG-2107, YANG-2108, or YANG-2111 as shown in Table 1b.~~

	~~YANG-1112~~	~~YANG-2107~~	~~YANG-2108~~	~~YANG-2111~~
~~HCDR1~~	~~SEQ ID No: 572~~	~~SEQ ID No: 899~~	~~SEQ ID No: 908~~	~~SEQ ID No: 1046~~
~~HCDR2~~	~~SEQ ID No: 573~~	~~SEQ ID No: 900~~	~~SEQ ID No: 909~~	~~SEQ ID No: 1047~~
~~HCDR3~~	~~SEQ ID No: 574~~	~~SEQ ID No: 901~~	~~SEQ ID No: 910~~	~~SEQ ID No: 1048~~
~~LCDR1~~	~~SEQ ID No: 577~~	~~SEQ ID No: 904~~	~~SEQ ID No: 913~~	~~SEQ ID No: 1051~~
~~LCDR2~~	~~SEQ ID No: 578~~	~~SEQ ID No: 203~~	~~SEQ ID No: 203~~	~~SEQ ID No: 1052~~
~~LCDR3~~	~~SEQ ID No: 579~~	~~SEQ ID No: 905~~	~~SEQ ID No: 914~~	~~SEQ ID No: 1053~~

9. ~~An antibody according to claim 8, wherein the variable heavy (VH) domain and variable light (VL) domain sequences respectively comprise the variable heavy (VH) domain and variable light (VL) domain sequences of antibody YANG-1112, YANG-2107, YANG-2108, or YANG-2111 as shown in Table 1b optionally with 1, 2, 3, 4 or 5 amino acid alterations outside the complementarity determining regions (CDRs) in the variable heavy (VH) domain sequence and optionally with 1, 2, 3, 4 or 5 amino acid alterations outside the complementarity determining regions (CDRs) in the variable light (VL) domain sequence.~~

	~~YANG-1112~~	~~YANG-2107~~	~~YANG-2108~~	~~YANG-2111~~
~~VH~~	~~SEQ ID No: 571~~	~~SEQ ID No: 898~~	~~SEQ ID No: 907~~	~~SEQ ID No: 1045~~
~~VL~~	~~SEQ ID No: 576~~	~~SEQ ID No: 903~~	~~SEQ ID No: 912~~	~~SEQ ID No: 1050~~

10. ~~An antibody according to claim 8, wherein the variable heavy (VH) domain and variable light (VL) domain sequences respectively comprise a sequence having at least 90% identity to the variable heavy (VH) and variable light (VL) domain sequences of antibody YANG-1112, YANG-2107, YANG-2108, or YANG-2111 as shown in Table 1b, provided that the antibody has the CDRs of antibody YANG-1112, YANG-2107, YANG-2108, or YANG-2111 as shown in Table 1b, respectively.~~

11. ~~An antibody according to any of claims 7 to 10, wherein the variable heavy (VH) domain and variable light (VL) domain sequences respectively comprise the variable heavy (VH) and~~

~~variable light (VL) domain sequences of antibody YANG-1112, YANG-2107, YANG-2108, or YANG-2111 as shown in Table 1b.~~

~~12. — A neutralising antibody that specifically binds to the S2 subunit of the SARS-CoV-2 spike protein.~~

~~13. — An antibody according to claim 12, wherein the antibody comprises a variable heavy (VH) domain sequence comprising complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3, and a variable light (VL) domain sequence comprising complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein HCDR3 is the HCDR3 of antibody YANG-2203, YANG-2204, YANG-2205, YANG-2206, YANG-2207, or YANG-2208 as shown in Table 1b.~~

	YANG-2203	YANG-2204	YANG-2205	YANG-2206	YANG-2207	YANG-2208
HCDR3	SEQ ID No: 1108	SEQ ID No: 1228	SEQ ID No: 1238	SEQ ID No: 1248	SEQ ID No: 1258	SEQ ID No: 1268

~~14. — An antibody according to claim 13, wherein the 6 CDRs are those of one of antibody YANG-2203, YANG-2204, YANG-2205, YANG-2206, YANG-2207, or YANG-2208 as shown in Table 1b.~~

	YANG-2203	YANG-2204	YANG-2205	YANG-2206	YANG-2207	YANG-2208
HCDR1	SEQ ID No: 1106	SEQ ID No: 1226	SEQ ID No: 1236	SEQ ID No: 1246	SEQ ID No: 1256	SEQ ID No: 1266
HCDR2	SEQ ID No: 1107	SEQ ID No: 1227	SEQ ID No: 1237	SEQ ID No: 1247	SEQ ID No: 1257	SEQ ID No: 1267
HCDR3	SEQ ID No: 1108	SEQ ID No: 1228	SEQ ID No: 1238	SEQ ID No: 1248	SEQ ID No: 1258	SEQ ID No: 1268
LCDR1	SEQ ID No: 1111	SEQ ID No: 1231	SEQ ID No: 1241	SEQ ID No: 1251	SEQ ID No: 1261	SEQ ID No: 1271
LCDR2	SEQ ID No: 1112	SEQ ID No: 1232	SEQ ID No: 1242	SEQ ID No: 1252	SEQ ID No: 1262	SEQ ID No: 1272
LCDR3	SEQ ID No: 1113	SEQ ID No: 1233	SEQ ID No: 1243	SEQ ID No: 1253	SEQ ID No: 1263	SEQ ID No: 1273

~~15. — An antibody according to claim 14, wherein the variable heavy (VH) domain and variable light (VL) domain sequences respectively comprise the variable heavy (VH) domain and variable light (VL) domain sequences of antibody YANG-2203, YANG-2204, YANG-2205, YANG-2206, YANG-2207, or YANG-2208 as shown in Table 1b optionally with 1, 2, 3, 4 or 5 amino acid alterations outside the complementarity determining regions (CDRs) in the variable~~

heavy (VH) domain sequence and optionally with 1, 2, 3, 4 or 5 amino acid alterations outside the complementarity determining regions (CDRs) in the variable light (VL) domain sequence.

	YANG-2203	YANG-2204	YANG-2205	YANG-2206	YANG-2207	YANG-2208
VH	SEQ ID No: 1105	SEQ ID No: 1225	SEQ ID No: 1235	SEQ ID No: 1245	SEQ ID No: 1255	SEQ ID No: 1265,
VL	SEQ ID No: 1110	SEQ ID No: 1230	SEQ ID No: 1240	SEQ ID No: 1250	SEQ ID No: 1260	SEQ ID No: 1270

16. — An antibody according to claim 14, wherein the variable heavy (VH) domain and variable light (VL) domain sequences respectively comprise a sequence having at least 90% identity to the variable heavy (VH) and variable light (VL) domain sequences of antibody YANG-2203, YANG-2204, YANG-2205, YANG-2206, YANG-2207, or YANG-2208 as shown in Table 1b, provided that the antibody has the CDRs of antibody YANG-2203, YANG-2204, YANG-2205, YANG-2206, YANG-2207, or YANG-2208 as shown in Table 1b, respectively.

17. — An antibody according to any of claims 12 to 16, wherein the variable heavy (VH) domain and variable light (VL) domain sequences respectively comprise the variable heavy (VH) and variable light (VL) domain sequences of antibody YANG-2203, YANG-2204, YANG-2205, YANG-2206, YANG-2207, or YANG-2208 as shown in Table 1b.

18. — A neutralising antibody that specifically binds to the receptor binding domain (RBD) of the SARS-CoV-2 spike protein, wherein the antibody does not compete for binding to the SARS-CoV-2 spike protein with the human ACE2 receptor.

19. — An antibody according to claim 1, wherein the antibody comprises a variable heavy (VH) domain sequence comprising complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3, and a variable light (VL) domain sequence comprising complementarity determining regions LCDR1, LCDR2 and LCDR3, and wherein HCDR3 is the HCDR3 of antibody YANG-1401 as shown in Table 1b (SEQ ID NO: 780).

20. — An antibody according to claim 2, wherein the 6 CDRs are those of antibody YANG-1401 as shown in Table 1b (SEQ ID NOs: 778-780, 783, 18, and 784).

~~21. — An antibody according to claim 3, wherein the variable heavy (VH) domain and variable light (VL) domain sequences respectively comprise the variable heavy (VH) domain and variable light (VL) domain sequences of antibody YANG-1401 as shown in Table 1b (SEQ ID Nos: 777 and 782), optionally with 1, 2, 3, 4 or 5 amino acid alterations outside the complementarity determining regions (CDRs) in the variable heavy (VH) domain sequence and optionally with 1, 2, 3, 4 or 5 amino acid alterations outside the complementarity determining regions (CDRs) in the variable light (VL) domain sequence.~~

~~22. — An antibody according to claim 3, wherein the variable heavy (VH) domain and variable light (VL) domain sequences respectively comprise a sequence having at least 90% identity to the variable heavy (VH) and variable light (VL) domain sequences of antibody YANG-1401 as shown in Table 1b, provided that the antibody has the 6 CDRs of antibody YANG-1401 as shown in Table 1b.~~

~~23. — An antibody according to any preceding claim, wherein the variable heavy (VH) domain and variable light (VL) domain sequences respectively comprise the variable heavy (VH) and variable light (VL) domain sequences of antibody YANG-1401 as shown in Table 1b.~~

~~246.~~ An antibody which (i) competes for binding to the SARS-CoV-2 spike protein with an antibody according to any one of claims 1 to ~~235~~; or (ii)

~~25. — An antibody which~~ binds to the same epitope on the SARS-CoV-2 spike protein as an antibody according to any one of claims 1 to ~~235~~.

~~267.~~ An antibody according to any one of claims 1 to ~~256~~, wherein

i. the antibody is a human IgG1 antibody;

~~27. — An antibody according to claim 26,~~ optionally wherein the antibody is a human IgG1 antibody comprising a constant region sequence of SEQ ID NO: 418;

~~28. — An antibody according to any one of claims 1 to 25,~~ wherein

ii. the antibody is a human IgG4 antibody;

~~29. An antibody according to claim 28, optionally~~ wherein the antibody is a human IgG4 antibody comprising a constant region sequence of SEQ ID NO: 436; ~~or~~

~~30. An antibody according to any one of claims 1 to 25, wherein~~

~~iii.~~ the antibody comprises kappa (κ) light chain constant regions, preferably wherein the kappa (κ) light chain constant regions sequence is SEQ ID NO: 448.

~~318.~~ A nucleic acid comprising a sequence that encodes a VH domain and/or an VL domain of an antibody as defined in any preceding claim.

~~329.~~ A vector comprising the nucleic acid of claim ~~318~~; optionally wherein the vector is a CHO vector.

~~3310.~~ A host cell comprising the nucleic acid of claim ~~318~~ or the vector of claim ~~329~~.

~~3411.~~ A pharmaceutical composition comprising
an antibody according to any one of claims 1 to ~~307~~, ~~and a pharmaceutically acceptable excipient.~~

~~35. A pharmaceutical composition comprising~~
an isolated nucleic acid encoding an antibody according to any one of claims 1 to ~~307~~,
or the isolated nucleic acid of claim ~~318~~,
~~and a pharmaceutically acceptable excipient.~~

~~3612.~~ A pharmaceutical composition according to claim ~~34 or 3511~~,
~~i.~~ formulated for intravenous, intramuscular or subcutaneous administration; ~~and/or~~

~~37. A pharmaceutical composition according to any of claims 34 to 36,~~
~~ii.~~ further comprising at least one further therapeutic agent.

~~38. A pharmaceutical composition according to claim 37, optionally~~ wherein the further therapeutic agent is at least one, preferably one or two, further antibodies.

~~39. A pharmaceutical composition according to claim 38, optionally~~ wherein the at least one further antibody is selected from:

a. an antibody that specifically binds to the receptor binding domain (RBD) of the S1 subunit of the SARS-CoV-2 spike protein and competes for binding to the SARS-CoV-2 spike protein with the human ACE2 receptor;

b. an antibody that specifically binds to the receptor binding domain (RBD) of the S1 subunit of the SARS-CoV-2 spike protein and does not compete for binding to the SARS-CoV-2 spike protein with the human ACE2 receptor;

c. an antibody that specifically binds to the N-terminal domain (NTD) of the S1 subunit of the SARS-CoV-2 spike protein;

d. an antibody that specifically binds to the S2 subunit of the SARS-CoV-2 spike protein; and

e. an antibody preferentially binds to the trimer form of the SARS-CoV-2 spike protein over the isolated RBD domain, S1 subunit and S2 subunit of the SARS-CoV-2 spike protein.

~~40. A kit comprising the pharmaceutical composition of any one of claims 34 to 39, claim 11 or 12, and~~

~~41. A kit according to claim 40, optionally~~ further comprising
~~i. at least one further therapeutic agent.~~

~~42. A kit according to claim 41, optionally~~ wherein the further therapeutic agent is a further pharmaceutical composition comprising at least one, preferably one or two, further antibodies.
~~optionally~~

~~43. A kit according to claim 42, wherein the at least one further antibody is selected from:~~

a. an antibody that specifically binds to the receptor binding domain (RBD) of the S1 subunit of the SARS-CoV-2 spike protein and competes for binding to the SARS-CoV-2 spike protein with the human ACE2 receptor;

b. an antibody that specifically binds to the receptor binding domain (RBD) of the S1 subunit of the SARS-CoV-2 spike protein and does not compete for binding to the SARS-CoV-2 spike protein with the human ACE2 receptor;

c. an antibody that specifically binds to the N-terminal domain (NTD) of the S1 subunit of the of SARS-CoV-2 spike protein;

d. an antibody that specifically binds to the S2 subunit of the of SARS-CoV-2 spike protein; and

e. an antibody preferentially binds to the trimer form of the SARS-CoV-2 spike protein over the isolated RBD domain, S1 subunit and S2 subunit of the SARS-CoV-2 spike protein;
and/or

~~44. — A kit according to any of claims 40 to 43, further comprising~~

~~ii. — a label or instructions for use to treat and/or prevent a SARS-CoV-2-related disease or condition, such as COVID-19, in a human; optionally wherein the label or instructions comprise a marketing authorisation number (e.g., an FDA or EMA authorisation number); optionally wherein the kit comprises an IV or injection device that comprises the antibody or fragment.~~

~~45~~14. An antibody according to any one of claims 1 to ~~30~~7, or the composition according to ~~any one of claims 34 to 39~~ claim 11 or claim 12, for use as a medicament.

~~46~~15. ~~Use of The~~the antibody according to any one of claims 1 to ~~30~~7, or the composition according to ~~any one of claims 34 to 39~~ claim 11 or claim 12, ~~in the manufacture of a medicament for use in a method of treating or preventing~~ a SARS-CoV-2-related disease or condition, said method comprising administering wherein the antibody or composition is to be administered to a patient.

~~47. — The antibody according to any one of claims 1 to 30, or the composition according to any one of claims 34 to 39, for use in a method of preventing a SARS-CoV-2-related disease or condition, said method comprising administering the antibody or composition to a patient.~~

~~48. — Use of an antibody according to any one of claims 1 to 30, or the composition according to any one of claims 34 to 39, in the manufacture of a medicament for use in a method of treating a SARS-CoV-2-related disease or condition.~~

~~49. — Use of an antibody according to any one of claims 1 to 30, or the composition according to any one of claims 34 to 39, in the manufacture of a medicament for use in a method of preventing a SARS-CoV-2-related disease or condition.~~

~~50. — A method of treating a SARS-CoV-2-related disease or condition in a human, comprising administering to said human a therapeutically effective amount of an antibody~~

~~according to any one of claims 1 to 30, or the composition according to any one of claims 34 to 39.~~

~~51. — A method of preventing a SARS-CoV-2-related disease or condition in a human, comprising administering to said human a therapeutically effective amount of an antibody according to any one of claims 1 to 30, or the composition according to any one of claims 34 to 39.~~

~~5216. An antibody for use according to claim 46 or 47, or The use according to claim 15, wherein~~

~~the composition for use according to claim 46 or 47, or~~

~~the use of an antibody according to claim 48 or 49, or~~

~~the method according to claim 50 or 51,~~

~~i. wherein the SARS-CoV-2-related disease or condition is COVID-19; and/or~~

~~53. — An antibody for use according to claim 46, 47 or 52, or~~

~~the composition for use according to claim 46, 47 or 52, or~~

~~the use of an antibody according to claim 48, 49 or 52, or~~

~~the method according to claim 50, 51 or 52,~~

~~ii. said method further comprising administering the medicament is to be administered with at least one further therapeutic agent; optionally wherein~~

~~54. — An antibody for use according to claim 46, 47, 52, or 53, or~~

~~the composition for use according to claim 46, 47, 52 or 53, or~~

~~the use of an antibody according to claim 48, 49, 52 or 53, or~~

~~the method according to claim 50, 51, 52 or 53,~~

~~wherein~~

~~a. administration of the further therapeutic agent is simultaneous, separate or sequential;~~

~~55. — An antibody for use according to claim 46, 47, 52, 53 or 54, or~~

~~the composition for use according to claim 46, 47, 52, 53 or 54, or~~

~~the use of an antibody according to claim 48, 49, 52, 53 or 54, or~~

~~the method according to claim 50, 51, 52, 53 or 54,~~

~~wherein~~

~~b. the further therapeutic agent is at least one, preferably one or two, further antibodies;~~

~~56. — An antibody for use according to claim 46, 47, 52, 53, 54 or 55, or the composition for use according to claim 46, 47, 52, 53, 54 or 55, or the use of an antibody according to claim 48, 49, 52, 53, 54 or 55, or the method according to claim 50, 51, 52, 53, 54 or 55,~~

optionally wherein the at least one further antibody is selected from:

- (i) an antibody that specifically binds to the receptor binding domain (RBD) of the S1 subunit of the SARS-CoV-2 spike protein and competes for binding to the SARS-CoV-2 spike protein with the human ACE2 receptor;
- (ii) an antibody that specifically binds to the receptor binding domain (RBD) of the S1 subunit of the SARS-CoV-2 spike protein and does not compete for binding to the SARS-CoV-2 spike protein with the human ACE2 receptor;
- (iii) an antibody that specifically binds to the N-terminal domain (NTD) of the S1 subunit of the of SARS-CoV-2 spike protein;
- (iv) an antibody that specifically binds to the S2 subunit of the of SARS-CoV-2 spike protein; and
- (v) an antibody preferentially binds to the trimer form of the SARS-CoV-2 spike protein over the isolated RBD domain, S1 subunit and S2 subunit of the SARS-CoV-2 spike protein.

~~57~~17. Use of an antibody according to any of claims 1 to ~~30~~7, for determining the presence or absence of SARS-CoV-2 in a sample.

~~58~~18. A method of determining the presence or absence of SARS-CoV-2, in a sample, the method comprising

contacting the sample with an antibody according to any of 1 to ~~30~~7; and
testing for binding between the antibody and SARS-CoV-2 in the sample;
wherein detection of binding indicates the presence of SARS-CoV-2 in the sample and
wherein absence of binding indicates the absence of SARS-CoV-2 in the sample.

~~59~~19. Use according to claim ~~57~~17 or a method according to claim ~~58~~18, wherein
i. the antibody comprises or is conjugated to a detectable label;

~~60. — Use according to claim 57 or claim 59, or a method according to claim 58 or claim 59, wherein~~

ii. the sample has been obtained from a human who has been or is suspected of having been infected with SARS-CoV-2 and/or who exhibits one or more symptoms of a SARS-CoV-2-related disease or condition, such as COVID-19; and/or

~~61. Use according to claim 57, 59, or 60, or a method according to claim 58, 59, or 60, wherein~~

~~iii.~~ the sample is a serum, plasma, or whole blood sample, or an oral or nasal swab, urine, faeces, or cerebrospinal fluid (CFS), or wherein the sample is from any suspected SARS-CoV-2 infected organ or tissue.

~~62~~20. A diagnostic kit for the use as set out in ~~any of claims 57, 59, 60~~ 17 or ~~61~~ claim 19, or the method as set out in ~~any of claims 58, 59, 60 or 61~~ claim 18 or claim 19, comprising an antibody according to any of claims 1 to ~~30~~ 7, and optionally one or more buffering solutions, optionally

~~63. A diagnostic kit according to claim 62,~~

~~i.~~ wherein the antibody comprises or is conjugated to a detectable label.

~~64. A diagnostic kit according to claim 62,~~

~~ii.~~ comprising

a first reagent comprising the antibody according to any of claims 1 to ~~30~~ 7, and

a second reagent comprising a detector molecule that binds to the first reagent.

~~65. A diagnostic kit according to claim 64, optionally~~ wherein the detector molecule is an antibody that comprises or is conjugated to a detectable label.

~~66. A kit or a pharmaceutical composition comprising:~~

~~a first antibody that specifically binds to the receptor binding domain (RBD) of the S1 subunit of the SARS-CoV-2 spike protein and competes for binding to the SARS-CoV-2 spike protein with the human ACE2 receptor; and~~

~~a second antibody that specifically binds to the S2 subunit of the of SARS-CoV-2 spike protein.~~

~~67. A kit or a pharmaceutical composition according to claim 66, wherein the kit or pharmaceutical composition is capable of syncytia formation inhibition of 45% or greater, or 50% or greater.~~

~~68. A kit or a pharmaceutical composition according to claim 66 or claim 67, wherein the first antibody is an antibody according to any one of claims 1 to 11.~~

~~69. — A kit or a pharmaceutical composition according to claim 66 or claim 67, wherein the first antibody is IMPI-059 or an antibody having HCDR3, the 6 CDRs, or the VH and/or VL domain sequences of IMPI-059 as shown in Table 1a.~~

	IMPI-059
VH	SEQ ID No: 53
VL	SEQ ID No: 58
HCDR1	SEQ ID No: 54
HCDR2	SEQ ID No: 55
HCDR3	SEQ ID No: 56
LCDR1	SEQ ID No: 59
LCDR2	SEQ ID No: 28
LCDR3	SEQ ID No: 60

~~70. — A kit or a pharmaceutical composition according to any one of claims 66 to 69, wherein the second antibody is an antibody according to any one of claims 12 to 17.~~

~~71. — A kit or a pharmaceutical composition according to claim 70, wherein the second antibody is YANG-2204, YANG-2206, or YANG-2207 or an antibody having HCDR3, the 6 CDRs, or the VH and/or VL domain sequences of YANG-2204, YANG-2206, or YANG-2207 as shown in Table 1b.~~

~~72. — A kit or a pharmaceutical composition according to any one of claims 66 to 71 for use in a method of treating a SARS-CoV-2-related disease or condition, said method comprising administering the first and second antibody or the composition comprising the first and second antibody to a patient, optionally wherein the SARS-CoV-2-related disease or condition is COVID-19.~~